Department of Health
and Human Services (HHS)
and Human Services (HHS)
RFA-NS-21-010 - HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
National Institute of Neurological Disorders and Stroke (NINDS)
The purpose of this notice is to inform applicants of a change to the Application Types Allowed for Funding Opportunity Announcement (FOA) RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)". The application types have been expanded to include Resubmission applications. This change is effective as of the October 15, 2021 due date.
The following sections of RFA-NS-21-010 have been modified:
Currently Reads:
Section II. Award Information
| Application Types Allowed |
New The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA. |
Section V. Application Review Information
1. Criteria
Additional Review Criteria
Resubmissions
Not Applicable.
Modified to Read (changes shown in bold italics):
Section II. Award Information
| Application Types Allowed |
New Resubmission The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA. |
Section V. Application Review Information
1. Criteria
Additional Review Criteria
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
All other aspects of this FOA remain unchanged.
Charles Cywin, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email: [email protected]